NEW OPPORTUNITIES/MARKETS/PRODUCTS Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.
All three markets mentioned here from Jan presentation are markets that Solventum sells products in.
I bring up Solventum because Zimmer Biomets former CEO Bryan Hanson is now CEO of Solventum and knows all about Sintx IP from his Zimmer days
Bryan Hanson & 3M's Solventum
wound care, oral care, health care IT, and biopharma filtration
Section 2 - Silicon Nitride, a Close to Ideal Ceramic Material for Medical Application
examples of their medical applications that relate to spinal, orthopedic and dental implants, bone grafts and scaffolds, platforms for intelligent synthetic neural circuits, antibacterial and antiviral particles and coatings, optical biosensors, and nano-photonic waveguides for sophisticated medical diagnostic devices are all covered in the research reviewed herein. The examples provided convincingly show that silicon nitride is destined to become a leader to replace titanium and other entrenched biomaterials in many fields of medicine.
Section 3 - PioneerPhoenix73 has some misinformation in its post, purposeful or not. Some factual corrections needed in its post:
1. Zimmer Biomet did not acquire Implex as Zimmer Biomet did not exist in 2003. Zimmer acquired Implex 12 years before Zimmer became Zimmer Biomet. 2. Implex material was porous version of tantalum metal it called Hydrocel and Zimmer calls Trabecular Metal. Completely different material and a metal not ceramic. 3. Sintx tech is heavily patented making it very difficult for a partner company to steal its tech. As well as any partnership agreement would likely have extra clauses to prevent such a scenario. The scenario is highly unlikely in Western countries. 4. Sintx is the only company with medical grade Si3n4 with over 100 patents pending worldwide making it unlikely that Zimmer Biomet could license the tech from any other company. Furthermore testing of products related to Sintx and Biomet IP were tested in 2016, & 2018 showing further collaberation well after that 2011 quote. Zimmer Biomet even hired a Si3N4 coatings expert end of 2018 showing continued interest past 2018. Large companies like Zimmer Biomet use small companies like Sintx to de-risk IP and then acquire it. Thats exactly how J&J operates. Does that guarantee anything? No it does not. However according to one scientist, Silicon Nitride is destined to replace current materials used in many fields of medicine.
These are risk-averse companies that look to smaller companies like us to develop an idea, uh, and, uh, de-risk it, so to speak, and then buy that technology.
~ Dr Sonny Bal former CEO of Sintx.
In Figure 1, you can see J&J makes most of its money from pharmaceuticals and medical devices. They have grown these two sectors over the past decade through major capital investments in acquisitions and people development. Instead of investing in developing technology in-house, they use their size to acquire smaller companies who they believe have a promising trajectory in the healthcare space.
We believe we are the only FDA-registered and ISO 13485:2016 certified silicon nitride medical device manufacturing facility in the world, and the only provider of structural ceramics-based medical devices used for spinal fusion applications
This is precisely why their partnerships are so important! We know theyve been working with Morgan Ceramics. We know NP Aerospace was spun off from Morgan after Sintx was working with Morgan and that Sintx began its foray into the armor market with the help of NP Alum Donald Bray who left Morgan with the divestment of NP.
Just because they have something doesn't mean they've done anything with it.
Morgan Ceramics = Aerospace products Zimmer Biomet = Arthroplasty oriented products ZimVie = Dental? Solventum = Wound Care, Catheters, & possibly Cancer treatment products. Cardinal Health = PPE & Medical protection apparel. NP Aerospace = Armor plates & other possible products connected to TA&T.
With Zimmer Biomet comes ZimVie and likely Solventum because of CEO Bryan Hanson. Sintx has been working with Zimmer/Biomet for going on 20 years and seems to be working with Solventum too based on it collaborating with a company on these products:
NEW OPPORTUNITIES/MARKETS/PRODUCTS Several new collaborations in developing products for wound care, cancer treatment, and an antipathogenic coating for catheters.
Sintx hiring of Joseph Palomo suggests its working with Cardinal Health.
Palomo joins SINTX with over 40 years of experience in protective apparel and PPE, such as surgical gowns, surgical drapes, isolation gowns, films, tubing, and surgical face masks.
He has held management roles at Cardinal Health R&D for new product development on a global scale
Its honestly overwhelming the size of the markets Sintx material can be used in. Hypothetical scenario using 5% market penetration with a 5% licensing fee equates to $811m in yearly licensing revenue. Thus Si3N4 is worth at least $800m in potential yearly revenue for an acquiring company through licensing revenue according to this scenario. Its ability to penetrate the above markets will vary but Ortho & Catheter markets are markets that Si3N4 should significantly penetrate; with Wound Care & Dental being up there as well. Condom market is more hypothetical based on Si3N4 ability to kill Herpes and possibly other STI. However would need to be studied further to ensure it doesnt impact the delicate microbe balance inside a vaginal canal. A new patent was awarded Sintx for the use of Si3n4 against funguses that impact the wine industry providing yet another market it can tap into. This could be a market that they could break into sooner than some of the others listed above but it wouldnt be as lucrative.